文献速递心力衰竭与心肌病

扩张型心肌病的遗传咨询实施

Genetic counselling implementation in dilated cardiomyopathy.
PubMed 文献 · Eur Heart J · 2026-01-01

本文综述了扩张型心肌病(DCM)遗传检测的应用现状,指出遗传检测已成为DCM诊断评估的组成部分,检测阳性率因病因或家族史不同为8%至36%。文章提出应将遗传检测整合入DCM临床诊疗的综合路径,以指导风险分层、预后、治疗及家族筛查。

要点

  • 遗传检测适用于所有DCM患者,尤其当结果可能影响风险分层、预后或治疗时。
  • DCM遗传架构正从单基因模式向多基因谱转变,但当前策略仍主要基于不完全外显的单基因遗传模型。
  • 致病或可能致病变异可在结合表型情况下指导器械治疗决策、家族筛查和生育选择。

核心结论

  • 遗传检测已成为DCM诊断评估的组成部分,应在个体患者表型背景下解读变异,并将遗传检测整合入临床诊疗综合路径。

研究设计与样本

  • 本文为综述,未报告系统检索范围。

主要发现

  • 大型研究显示DCM患者遗传检测阳性率因病因或家族史不同为8%至36%。
  • DCM遗传架构知识显著扩展,推动从单基因教条向更广泛的多基因谱转变。
  • 当前遗传检测策略仍主要依赖不完全外显的单基因遗传模型。

关键数值与推荐

  • 遗传检测通常适用于所有DCM患者,前提是遗传结果可能影响患者或其家族成员的风险分层、预后或治疗,或提供 reassured 或早期发现疾病的机会。
  • 遗传检测策略包括广泛多基因面板或限于特定疾病相关基因的靶向面板。
  • 致病或可能致病变异常具有可操作的临床意义,当遗传结果与患者 broader 表型一致时,潜在临床影响包括器械治疗决策、家族筛查建议和生育选择。

临床怎么用

  • 对DCM患者应考虑遗传检测,以指导风险分层、治疗决策及家族筛查。
  • 遗传变异解读需结合个体患者表型及其他 contributing 因素。
  • 根据遗传结果与表型一致性,可考虑器械治疗、家族筛查和生育选项。

局限性

  • 当前遗传检测策略仍主要基于不完全外显的单基因遗传模型,与DCM多基因谱的认知存在差距。
  • 遗传检测阳性率受病因或家族史影响,变异解读需结合表型和其他因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Genetic testing has become an integral part of the diagnostic workup of patients with dilated cardiomyopathy (DCM). While the initial goal of genetic testing was to identify family members at risk, recent advances have now extended their relevance to clinical decision-making. Our knowledge of the genetic architecture of DCM has expanded significantly, promoting a shift from the monogenic dogma towards a broader polygenic spectrum. However, current genetic testing strategies still primarily rely on the model of monogenic inheritance with an incomplete penetrance. Large studies have shown a yield varying from 8% to 36% of genetic testing in patients with DCM, depending on aetiology or family history. Genetic testing is generally warranted for every patient with DCM where genetic results could have an impact on risk stratification, the prognosis or the treatment of the patient, or its family members with an opportunity for reassurance or early disease detection. There are various strategies for genetic testing including broad multigene panels, or more targeted panels limited to specific disease-associated genes. Identified variants are classified by genetic laboratories, where pathogenic or likely pathogenic variants often have actionable clinical implications. It is crucial to interpret these variants in the context of the individual patient considering the phenotype and other contributing factors. When the genetic results are consistent with the patients' broader phenotype, potential clinical implications may include decision for device therapy, recommendations for family screening, and reproductive options. A comprehensive approach to integrate genetic testing in the clinical care of patients with DCM is proposed.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Verdonschot JAJ, van Spaendonck-Zwarts KY, Hellebrekers DMEI, et al. Genetic counselling implementation in dilated cardiomyopathy. Eur Heart J. 2026. PMID: 41858107. doi:10.1093/eurheartj/ehag159

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。